Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 2 (2005), Issue 9 (September)

1. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS).
   J Clin Oncol, 23(25): 6190-8. [Abstract] [Full-text]
2. Effect of platelet-derived growth factor receptor-beta inhibition with STI571 on radioimmunotherapy.
   Cancer Res, 65(17): 7824-31. [Abstract] [Full-text]
3. Effects of imatinib on normal hematopoiesis and immune activation.
   Stem Cells, 23(8): 1082-8. [Abstract] [Full-text]
4. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy.
   Blood, 106(6): 2128-37. [Abstract] [Full-text]
5. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.
   J Cell Physiol, 205(2): 218-27. [Abstract] [Full-text]
6. Pathophysiology, diagnosis, and treatment of gastrointestinal stromal tumors.
   J Gastroenterol, 40(8): 775-80. [Abstract] [Full-text]
7. Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis.
   Gastroenterology, 129(3): 1042-6. [Abstract] [Full-text]
8. Sarcomas and pharmacogenetics.
   Pharmacogenomics, 6(6): 585-601. [Abstract] [Full-text]
9. AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells.
   Cancer, 104(6): 1230-6. [Abstract] [Full-text]
10. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia.
    Genes Chromosomes Cancer, 44(3): 329-33. [Abstract] [Full-text]
11. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia.
    Clin Cancer Res, 11(17): 6247-55. [Abstract] [Full-text]
12. Effect of angiosonography to monitor response during imatinib treatment in patients with metastatic gastrointestinal stromal tumors.
    Clin Cancer Res, 11(17): 6171-6. [Abstract] [Full-text]
13. Isolated central nervous system blast crisis in chronic myeloid leukemia.
    Hematol Oncol, 22(4): 179-81. [Abstract] [Full-text]
14. New targeted approaches in chronic myeloid leukemia.
    J Clin Oncol, 23(26): 6316-24. [Abstract] [Full-text]
15. Molecular genetics of acute lymphoblastic leukemia.
    J Clin Oncol, 23(26): 6306-15. [Abstract] [Full-text]
16. Protein-acrylamide copolymer hydrogels for array-based detection of tyrosine kinase activity from cell lysates.
    Biomacromolecules, 6(5): 2765-75. [Abstract] [Full-text]
17. Imatinib: the narrow line between immune tolerance and activation.
    Trends Mol Med, 11(9): 397-402. [Abstract] [Full-text]
18. Differential KIT expression in histological subtypes of adenoid cystic carcinoma (ACC) of the salivary gland.
    Oral Oncol, 41(9): 934-9. [Abstract] [Full-text]
19. Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment.
    Cancer Genet Cytogenet, 162(1): 57-62. [Abstract] [Full-text]
20. Resistance to tyrosine kinase inhibitors: calling on extra forces.
    Drug Resist Updat, 8(3): 119-29. [Abstract] [Full-text]
21. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
    Cancer Res, 65(18): 8423-32. [Abstract] [Full-text]
22. Metabolism and disposition of imatinib mesylate in healthy volunteers.
    Drug Metab Dispos, 33(10): 1503-12. [Abstract] [Full-text]
23. Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial.
    Lung Cancer, 50(1): 83-6. [Abstract] [Full-text]
24. Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression.
    Breast Cancer Res, 7(5): R788-95. [Abstract] [Full-text]
25. High affinity targets of protein kinase inhibitors have similar residues at the positions energetically important for binding.
    J Mol Biol, 352(5): 1134-56. [Abstract] [Full-text]
26. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series.
    Ann Oncol, 16(10): 1702-8. [Abstract] [Full-text]
27. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML.
    Blood, 106(7): 2520-6. [Abstract] [Full-text]
28. Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells.
    Blood, 106(7): 2436-43. [Abstract] [Full-text]
29. The kinase inhibitor imatinib mesylate inhibits TNF-{alpha} production in vitro and prevents TNF-dependent acute hepatic inflammation.
    Proc Natl Acad Sci U S A, 102(38): 13622-7. [Abstract] [Full-text]
30. Megachemotherapy followed by autologous stem cell transplantation in children with Ewing's sarcoma.
    Pediatr Transplant, 9(5): 618-21. [Abstract] [Full-text]
31. CML clonal evolution with resistance to single agent imatinib therapy.
    Clin Lab Haematol, 27(5): 347-9. [Abstract] [Full-text]
32. Differential tyrosine phosphorylation of leukemic cells during apoptosis as a result of treatment with imatinib mesylate.
    Biochem Biophys Res Commun, 336(3): 942-51. [Abstract] [Full-text]
33. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
    Leukemia, 19(10): 1774-82. [Abstract] [Full-text]
34. Targeted therapy in renal cell carcinoma.
    Expert Opin Investig Drugs, 14(10): 1251-8. [Abstract] [Full-text]
35. The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it?
    Expert Opin Ther Targets, 9(5): 1009-30. [Abstract] [Full-text]
36. Second-generation kinase inhibitors.
    Expert Opin Ther Targets, 9(5): 975-93. [Abstract] [Full-text]
37. Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia.
    Oncogene, 24(42): 6432-40. [Abstract] [Full-text]
38. Hypereosinophilic syndrome: an update.
    Am J Hematol, 80(2): 148-57. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.